McDonnell DP - Search Results

1

Bazedoxifene exhibits antiestrogenic activity in animal models of tamoxifen-resistant breast cancer: implications for treatment of advanced disease.

Wardell SE, Nelson ER, Chao CA, McDonnell DP. Wardell SE, et al. Among authors: mcdonnell dp. Clin Cancer Res. 2013 May 1;19(9):2420-31. doi: 10.1158/1078-0432.CCR-12-3771. Epub 2013 Mar 27. Clin Cancer Res. 2013. PMID: 23536434 Free PMC article.

2

Comparative analyses of mechanistic differences among antiestrogens.

Wijayaratne AL, Nagel SC, Paige LA, Christensen DJ, Norris JD, Fowlkes DM, McDonnell DP. Wijayaratne AL, et al. Among authors: mcdonnell dp. Endocrinology. 1999 Dec;140(12):5828-40. doi: 10.1210/endo.140.12.7164. Endocrinology. 1999. PMID: 10579349

3

Circumventing tamoxifen resistance in breast cancers using antiestrogens that induce unique conformational changes in the estrogen receptor.

Connor CE, Norris JD, Broadwater G, Willson TM, Gottardis MM, Dewhirst MW, McDonnell DP. Connor CE, et al. Among authors: mcdonnell dp. Cancer Res. 2001 Apr 1;61(7):2917-22. Cancer Res. 2001. PMID: 11306468

4

The human estrogen receptor-alpha is a ubiquitinated protein whose stability is affected differentially by agonists, antagonists, and selective estrogen receptor modulators.

Wijayaratne AL, McDonnell DP. Wijayaratne AL, et al. Among authors: mcdonnell dp. J Biol Chem. 2001 Sep 21;276(38):35684-92. doi: 10.1074/jbc.M101097200. Epub 2001 Jul 25. J Biol Chem. 2001. PMID: 11473106 Free article.

5

Glucocorticoids manifest androgenic activity in a cell line derived from a metastatic prostate cancer.

Chang CY, Walther PJ, McDonnell DP. Chang CY, et al. Among authors: mcdonnell dp. Cancer Res. 2001 Dec 15;61(24):8712-7. Cancer Res. 2001. PMID: 11751389

6

Definition of the molecular and cellular mechanisms underlying the tissue-selective agonist/antagonist activities of selective estrogen receptor modulators.

McDonnell DP, Connor CE, Wijayaratne A, Chang CY, Norris JD. McDonnell DP, et al. Recent Prog Horm Res. 2002;57:295-316. doi: 10.1210/rp.57.1.295. Recent Prog Horm Res. 2002. PMID: 12017549 Review.

7

Elucidation of the molecular mechanism of action of selective estrogen receptor modulators.

McDonnell DP, Wijayaratne A, Chang CY, Norris JD. McDonnell DP, et al. Am J Cardiol. 2002 Jul 3;90(1A):35F-43F. doi: 10.1016/s0002-9149(01)02221-4. Am J Cardiol. 2002. PMID: 12106639 Review.

8

Pharmacological uncoupling of androgen receptor-mediated prostate cancer cell proliferation and prostate-specific antigen secretion.

Sathya G, Chang CY, Kazmin D, Cook CE, McDonnell DP. Sathya G, et al. Among authors: mcdonnell dp. Cancer Res. 2003 Nov 15;63(22):8029-36. Cancer Res. 2003. PMID: 14633736

9

The molecular pharmacology of estrogen receptor modulators: implications for the treatment of breast cancer.

McDonnell DP. McDonnell DP. Clin Cancer Res. 2005 Jan 15;11(2 Pt 2):871s-7s. Clin Cancer Res. 2005. PMID: 15701880 Review.

10

Coactivation of liver receptor homologue-1 by peroxisome proliferator-activated receptor gamma coactivator-1alpha on aromatase promoter II and its inhibition by activated retinoid X receptor suggest a novel target for breast-specific antiestrogen therapy.

Safi R, Kovacic A, Gaillard S, Murata Y, Simpson ER, McDonnell DP, Clyne CD. Safi R, et al. Among authors: mcdonnell dp. Cancer Res. 2005 Dec 15;65(24):11762-70. doi: 10.1158/0008-5472.CAN-05-2792. Cancer Res. 2005. PMID: 16357189

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

291 results

Search Page